The previous demonstration of the efficacy and tolerability of the Oka strain of varicella-zoster virus (VZV) in clinical trials involving vaccination of both normal and immunocompromised individuals has laid the foundation for its use in preventing chickenpox. In this context, VZV could be useful as a vector for vaccinating against other infectious agents as well. As an initial application, a live recombinant VZV expressing Epstein-Barr virus (EBV) membrane glycoproteins (gp350/220) was generated by inserting a gene fusion of the VZV gpI promoter and hydrophobic leader-encoding sequence with the gp350/220 coding sequence into the thymidine kinase (TK) gene of VZV(Oka). Insertion of the foreign DNA into the thymidine kinase gene was demonstrated by Southern blot analysis and the ability of the recombinant virus to replicate in the presence of bromodeoxyuridine. RNA splicing, glycosylation, and plasma membrane presentation of gp350/220 in cells infected with the recombinant virus were similar to those seen in EBV-infected cells. In addition, the expression of VZV-specific glycoproteins was unaltered by the concomitant expression of this large foreign glycoprotein. Thus, VZV can be used as a live viral vector for active immunization against EBV and other pathogens.Varicella-zoster virus (VZV) is an Alphaherpesvirus and the etiological agent of chickenpox and zoster (shingles) (1). Most people are infected with VZV by age 20, and, after a variable latent period, reactivation of the virus causes an estimated 5 million cases of zoster worldwide each year (2). VZV causes a relatively benign disease in healthy children. However, it can be morbid in adults and life-threatening to neonates (3, 4) as well as to immunocompromised patients with leukemia (5, 6), bone marrow transplants (7), and lymphoma (8, 9). An attenuated strain (Oka) of VZV has been developed for use as a live viral vaccine (10). It has been tested clinically in several thousand normal children as well as in hundreds of children with acute lymphocytic leukemia (henceforth referred to as immunocompromised, as a consequence of chemotherapy) and has proven in clinical trials to be both well tolerated and effective in preventing chickenpox (11,12). Moreover, VZV(Oka) is the only live viral vaccine approved for use in such immunocompromised patients. For these reasons, we decided to test the feasibility of using VZV(Oka) as a live viral vector capable of expressing heterologous antigens and thereby protecting against other common human pathogens.Epstein-Barr virus (EBV) is a lymphotropic Gammaherpesvirus that infects almost the entire population of the world. Primary infection with EBV usually results in mild disease but may lead to life-threatening complications in immunocompromised individuals (13,14). In contrast, primary infection of adolescents can result in infectious mononucleosis (15). EBV is etiologically associated with Burkitt lymphoma and undifferentiated nasopharyngeal carcinoma; the latter affects up to 2% of the male population in south...